Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial - Concepedia

Concepedia

Publication | Closed Access

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

123

Citations

11

References

2010

Year

Philip J. Mease, Stanley Cohen, Norman Gaylis, Andrew Chubick, Alan Kaell, Maria Greenwald, Sunil Agarwal, Ming Yin, Ariella Kelman

The Journal of Rheumatology

Abstract

Two courses of rituximab about 6 months apart resulted in improved and sustained efficacy at 1 year, compared with 1 course, with a similar safety profile.

References

	Year	Citations

Page 1